RxDoctor Payments Data

Sarah Gonzalez

Family · Fairhope, ALNPI 1144760786

Payments from drug & device makers

$2,295in general payments, 2019–2025

Across 142 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$560
  • AbbVie$504
  • Pfizer$240
  • Johnson & Johnson$142
  • Abbott$125
  • Bayer$99
  • plus $627 from 16 others

What the payments were for

  • Food & beverage$2,295100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,295 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$45,294
Medicare patients
356
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$23,825
LinzessLinaclotide18$20,010
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,716
Pantoprazole Sodium182$2,481
Omeprazole121$1,874
Atorvastatin Calcium97$1,581
Colestipol Hcl18$1,253
Esomeprazole Magnesium28$1,186
Budesonide DrBudesonide11$907
Losartan Potassium52$660
Tamsulosin Hcl47$626
Levothyroxine Sodium57$590
Bupropion XlBupropion Hcl17$589
Lisinopril48$549
Amlodipine Besylate60$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$560$23,82522 claims
AbbVieLinzess$504$20,01018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →